Pulmonary Embolism Prevention With Rivaroxaban (Xarelto)
Rivaroxaban prevents pulmonary embolism (PE) when used for venous thromboembolism (VTE) prophylaxis in selected situations and for extended secondary prevention after a prior DVT/PE event. [1] Rivaroxaban does not reliably prevent PE after hospitalization for medical illness in unselected patients, based on MARINER trial results. [2]
Indications Relevant to PE Prevention
Rivaroxaban is used for PE prevention as part of VTE prophylaxis after orthopedic surgery (hip and knee replacement). [1] Rivaroxaban is used for reduction in the risk of recurrent DVT and of PE after patients have completed initial anticoagulation for DVT and/or PE. [1] Rivaroxaban is used for VTE prophylaxis in certain hospitalized settings depending on the specific labeled indication and patient characteristics (including renal function). [1]
Medication Selection Algorithm for PE Prevention
- Extended secondary prevention after completion of anticoagulation for prior DVT/PE: rivaroxaban (recurrent DVT and PE risk reduction). [1]
- VTE prophylaxis after major orthopedic surgery: rivaroxaban (PE is prevented as part of VTE prophylaxis). [1]
- Post-discharge prophylaxis for medically ill patients (unselected): rivaroxaban is not supported by MARINER primary outcome results. [2]
Key Evidence Supporting This Recommendation
In medically ill patients, rivaroxaban started at discharge and continued for 45 days did not show a statistically significant reduction in fatal or symptomatic VTE or VTE-related outcomes versus placebo in the MARINER trial publication. [2] In EINSTEIN CHOICE (extended treatment after completion of 6 to 12 months of anticoagulant therapy for DVT and/or PE), rivaroxaban 10 mg once daily was demonstrated to be superior to aspirin 100 mg once daily for the primary composite endpoint of recurrent DVT or non-fatal or fatal PE. [1]
Monotherapy Versus Combination Therapy for PE Prevention
Rivaroxaban is used as anticoagulant monotherapy for labeled VTE prophylaxis and for labeled extended secondary prevention of recurrent DVT/PE. [1] MARINER evaluated rivaroxaban versus placebo rather than combination therapy. [2]
Important Clarifications and Nuances
Rivaroxaban is intended for prophylaxis or secondary prevention of recurrent VTE after an acute treatment phase, based on labeled indications. [1] Rivaroxaban used in settings not supported by evidence may fail to prevent PE outcomes, as shown in MARINER for post-discharge medical illness populations. [2]
Common Pitfalls to Avoid
Assuming benefit for PE prevention in medically ill post-discharge patients without selecting a population that matches the intended prevention strategy can result in lack of efficacy. [2] Using rivaroxaban outside labeled prevention indications without supporting evidence for PE prevention increases the likelihood of ineffective prophylaxis. [1]
Treatment Goals of Therapy
The prevention goals supported by labeling include reduction of recurrent DVT and of PE after completion of prior anticoagulation for DVT and/or PE. [1] For orthopedic surgery settings, the prevention goal is reduction of VTE that includes PE, as VTE prophylaxis is the labeled clinical objective. [1] End of clinical topics.